Author: Chris MacDonald, Investor Place

All three could deliver outsized gains over the medium-to-long term.

These names provide everything long-term investors want, including an attractive entry point right now.

These names are worth buying right now, for those bullish on a rip-roaring market next year.

Reaching for yield can be dangerous, but these three names have juicy dividends and long-term total return upside potential that’s attractive in today’s market.

Biotech stocks exhibit strong growth trajectories, yet often trade at bargain prices. Here are three names investors should be buying up right now.